This may be true. As a shareholder, I don't mind if people need to get axed for the better good of a company. My concern is the growth of Shire. Sirromeo4th raised one very good point. Does Rolf equate quanity of hours with quality of management? DMs who get up at 5:00am and fly off to somewhere to work until 7:30 only to fly back home, may not be delivering any better mentoring/management, than those who spend a bit less time. I've never believed in quanity over quality in management. It's this way of thinking that makes me nervous. Sales are bad and now, I fear, they are only going to get worse.
It sounds like what you are talking about is years away from the market and not something we should be losing any sleep about tonight. What phase of development are they in? How far away are clinical trials? And plenty of pharmaceuticals have spent huge amounts of money on drugs they believed in and never saw those drugs come to market.
fgnoms, you said "whether Galantamine's long term prospects will be severely limited by Sanochemia producing Galantamine II, which is currently not licenced to Shire." Where did you get this information? Can you please give more details? It is the first time I have heard of Galantamine II.
I don't think it makes sense that the RPC side reps are going to get the ax, at least not "en masse" like the home office staff. Shire did not plan to integrate the two sales forces. Therefore, they cannot dump the RPC reps and let their own reps carry the products. They have to cross-train first, and considering how much else they have going on trying to integrate R&D into Maryland and admin into KY, it doesn't seem likely they have the time. Whether the floodgates are open for them to leave on their own, well, that's another story...
And does Rolf equate quantity of hours with quality? Ask the UK employees who are still at work when the US employees are going home.